A baby girl who was close to dying from cancer has been rescued by a cell therapy envisioned as a “one size fits all” treatment that had never been tested in people, doctors reported on Thursday.
The development is significant because it indicates that cell therapies, which represent an exciting new front in the battle against cancer, might not have to be customized for each patient, saving time and money.
It also represents one of the first times that a novel “genome editing” technique has been used to treat someone. The therapy was developed by Cellectis, a French biotechnology company.
But it is hard to say much based on one patient. Also, the girl has been in remission for only a few months, too little time to say she has been cured, said Waseem Qasim, one of the doctors who treated her at the Great Ormond Street Hospital in London.
Still, the girl’s doctors “think it is a remarkable outcome,” because she had not been helped by conventional therapies, Dr. Qasim said in an interview.
Cancer doctors have been electrified by a new approach that involves genetically altering patients’ T cells, the soldiers of the immune system, so that they can better attack cancers.
Some patients with certain blood cancers have made remarkable recoveries. They include a girl who received a treatment developed at the University of Pennsylvania and now licensed to Novartis. Other companies pursuing this approach, often called CAR-T, including Juno Therapeutics and Kite Pharma, have achieved large stock market valuations.
But the first versions of their experimental therapies require extracting the T cells from the patient, shipping them to a manufacturing plant where they can be altered, then sending them back and putting them back into the patient, something that will be logistically challenging and costly for thousands of patients. Cellectis’s therapy is meant to work for any patient with a particular type of leukemia.
Cellectis’s American depositary receipts soared 18 percent on Thursday, while shares of Juno fell 7 percent and those of Kite dipped 2 percent.
Still the personalized treatments could reach the market in the next couple of years, long before Cellectis’s treatment, which will not even enter early-stage clinical trials until next year.
The case of the girl’s recovery will be presented to doctors next month at the annual meeting of the American Society of Hematology in Orlando, Fla. But abstracts for that conference were made public Thursday, and the hospital publicized the case.
The girl, Layla Richards of London, had acute lymphoblastic leukemia. Doctors tried the usual chemotherapy, a bone marrow transplant and a new type of biotech drug, but nothing worked. Layla did not have enough T cells to allow doctors to extract them and make a personalized therapy.
Her parents, Ashleigh Richards and Lisa Foley, were counseled to consider palliative care to keep her comfortable until she died, Dr. Qasim said. But the parents were not willing to do that.
In what might be a lucky coincidence, the hospital was already manufacturing Cellectis’s cells in preparation for clinical trials. “We had them in our freezers,” Dr. Qasim said. He is also a professor at University College London, which worked with Cellectis on the treatment.
So, with permission from her parents and Cellectis, Layla became the first person to receive the treatment, on what is sometimes called a compassionate use basis.
The Latest on: Experimental therapies
via Google News
The Latest on: Experimental therapies
- Researchers Bank On ‘Smart Bomb’ Phage Therapy As A Hero In The Antibiotic-Resistant Era on November 18, 2019 at 7:38 am
In other pharmaceutical news, Novartis nabs U.S. approval for its experimental sickle cell drug. Bloomberg: Viral ‘Smart Bombs’ Are Becoming Weapons Against Superbugs At the University of California ...
- Experimental cholesterol-lowering drug effective at lowering bad cholesterol, study shows on November 18, 2019 at 7:36 am
Twice-yearly injections of an experimental cholesterol-lowering drug ... and elevated LDL (greater than 70 milligrams per deciliters), despite maximum tolerated oral statin therapies. Participants ...
- Medicare Out-Of-Pocket Costs For Cancer Treatment Every Retiree Should Know on November 18, 2019 at 5:04 am
The study showed that 14 of the 15 specialty drugs for cancer treatment each had a median out-of-pocket annual cost of over $8,000. Of those 14, median annual costs ranged from $8,181 for a prostate ...
- Experimental study finds possible treatment to peanut allergies on November 15, 2019 at 10:08 am
But experimental new research suggests adults might someday be able to take an antibody ... researchers said they’ll need to replicate the results with more participants and determine the ideal timing ...
- A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension on November 15, 2019 at 2:21 am
Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Current treatments increase life expectancy but have limited impact on the progressive pulmonary vascular remodelling that drives PAH ...
- The most promising breakthrough in Alzheimer’s treatment is not a drug on November 14, 2019 at 8:23 am
This year alone Roche, AC Immune, Biogen, and, most recently, Amgen and Novartis have all halted their experimental Alzheimer’s treatments due to poor clinical trial data. Notably, Biogen sent shock ...
- Experimental antibody treatment may protect against peanut allergy on November 14, 2019 at 8:14 am
But researchers report that a new drug injection might offer at least temporary protection against the most severe reactions. Just one shot of an experimental antibody treatment allowed people with ...
- Maryland woman denied experimental cancer treatment that could be her 'only fighting chance' on November 12, 2019 at 5:28 pm
A Bowie, Maryland father said an experimental cancer treatment might be his daughter’s only fighting chance in her battle against an aggressive and rare form of cancer. But, he said a New York ...
- FDA Again Halts Solid Bio’s Duchenne Gene Therapy Clinical Trial on November 12, 2019 at 7:26 am
The FDA has stopped a clinical trial testing a Solid Biosciences gene therapy for Duchenne muscular dystrophy after a patient developed complications associated with the experimental treatment.
- Solid Biosciences Stock Crashes Over Safety Concerns About Its Gene Therapy on November 12, 2019 at 7:20 am
Solid Biosciences showed signs Tuesday morning of facing serious setbacks for its Duchenne muscular dystrophy gene therapy, sending the biotech’s shares down about 70% in early trading. Solid (ticker: ...
via Bing News